Orphan Drugs Market

Orphan Drugs Market — Global Industry Insights, Trends,
Size, Share, Outlook, and Opportunity Analysis, 20182026
The drugs which are developed for treatment of rare diseases and conditions are referred to as
orphan drugs. The rare diseases such as Tourette syndrome, Huntington’s disease, muscular
dystrophy, myoclonus, and ALS (Lou Gehrig’s disease) are some of those diseases for treatment
of which adequate drugs have not been developed, and hence these diseases are treated by
orphan drugs. Orphan drugs are developed by the pharmaceutical companies for public health
need, and the sales generated by this drugs are very minimal when compared to normal drugs.
The orphan diseases manifest in patient populations representing 6-8% of the global population.
Symptoms of some orphan diseases may appear at birth or in childhood including cystic
fibrosis, infantile spinal muscular atrophy, familial adenomatous polyposis (FAP), and some
others.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/500
Developing novel indications for designated orphan drugs is expected to drive the orphan drugs
market
There are around 5,000 rare diseases listed globally and 80% of those are to genetic origins.
The probability of getting infected by these diseases in adults is 50%.The need for the
development of orphan drugs which will treat such diseases and proactive initiatives undertaken
by government and regulatory authorities are the major factors driving the orphan drugs
market. For instance, the authorities of U.S. FDA for orphan drug development department are
providing the incentives to healthcare and biotechnology industries in order to enhance their
research and development in orphan drugs. There are few drugs that have been withdrawn
from the market due to certain risk developed over prolong administration of these drugs.
However, these drugs have shown good results for treatment of those diseases which in
particular do not have any standard drug, owing to drive the orphan drugs market. For
instance, thalidomide used as a hypnotic drug was withdrawn from market when teratogenic
risk was discovered, however, this drug has shown prominent result in treating leprosy.
Numerous collaborative research programs across North America and Europe is owing to growth
of orphan drugs market
Regional segmentation of orphan drugs market by Coherent Market Insights comprises of North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America
dominates the market globally due to factors such as established regulatory and reimbursement
framework and incentives given by U.S. Food and Drug Administration (FDA) for research and
development in orphan drugs sector. The various collaborative research programs across United
States and Europe provides research data on rare diseases to manufacturers, patients and health
experts which gives timely medical care, thus boost the orphan drug market. Whereas the
prevalence of genetic diseases and growth of population are some factors which might allow the
orphan drugs manufacturers to invest in the Asia Pacific region.
Report includes chapters which deeply display the following deliverable about industry :
• Orphan Drugs Market Research Objective and Assumption
• Orphan Drugs Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Orphan Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Orphan Drugs Market, By Regions
• Orphan Drugs Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Orphan Drugs Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Orphan Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Orphan Drugs Market Forecast including Production, Consumption, Import and Export Forecast
by Type, Applications and Region.
• Research Findings and Conclusion
Initiatives taken by government to increase the investment in orphan drugs development driving
the growth of orphan drugs market.
Key players operating the orphan drugs market are Acorda Therapeutics, Actelion
Pharmaceuticals Ltd., Amgen, Alexion Pharmaceuticals, Baxter international, Bayer healthcare
pharmaceuticals, Biomarin Pharmaceuticals, Novartis, F.Hoffmann-La Roche AG, Johnson and
Johnson and many others. The increase in investments, and some initiatives taken by
government helping the orphan drug manufacturers. For instance, U.S. government provides
50% of tax credit on the research and development expenses spent on the orphan drugs
development by manufacturers. However the high cost of the orphan drugs and generation of
small sales from it is amongst those factors which is lowering the interest of companies for
market.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/500
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

The drugs which are developed for treatment of rare diseases and conditions are referred to as orphan drugs.

Download Report